Global Non Receptor Tyrosine Protein Kinase TYK2 Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Non Receptor Tyrosine Protein Kinase TYK2 Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Non Receptor Tyrosine Protein Kinase TYK2 report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Non Receptor Tyrosine Protein Kinase TYK2 market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Follicular Lymphoma and Hypersensitivity are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Non Receptor Tyrosine Protein Kinase TYK2 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Non Receptor Tyrosine Protein Kinase TYK2 key manufacturers include Array BioPharma Inc, Bristol-Myers Squibb Company, Nimbus Therapeutics LLC, Pfizer Inc, Portola Pharmaceuticals Inc, Sareum Holdings Plc, Takeda Pharmaceutical Company Ltd and Theravance Biopharma Inc, etc. Array BioPharma Inc, Bristol-Myers Squibb Company, Nimbus Therapeutics LLC are top 3 players and held % sales share in total in 2022.
Non Receptor Tyrosine Protein Kinase TYK2 can be divided into ARRY-624, BMS-986165, Cerdulatinib and NDI-031232, etc. ARRY-624 is the mainstream product in the market, accounting for % sales share globally in 2022.
Non Receptor Tyrosine Protein Kinase TYK2 is widely used in various fields, such as Follicular Lymphoma, Hypersensitivity, Lupus Nephritis and Marginal Zone B-cell Lymphoma, etc. Follicular Lymphoma provides greatest supports to the Non Receptor Tyrosine Protein Kinase TYK2 industry development. In 2022, global % sales of Non Receptor Tyrosine Protein Kinase TYK2 went into Follicular Lymphoma filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Non Receptor Tyrosine Protein Kinase TYK2 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Array BioPharma Inc
Bristol-Myers Squibb Company
Nimbus Therapeutics LLC
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Takeda Pharmaceutical Company Ltd
Theravance Biopharma Inc
Segment by Type
ARRY-624
BMS-986165
Cerdulatinib
NDI-031232
Others
Follicular Lymphoma
Hypersensitivity
Lupus Nephritis
Marginal Zone B-cell Lymphoma
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Non Receptor Tyrosine Protein Kinase TYK2 market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Non Receptor Tyrosine Protein Kinase TYK2, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Non Receptor Tyrosine Protein Kinase TYK2 industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Non Receptor Tyrosine Protein Kinase TYK2 in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Non Receptor Tyrosine Protein Kinase TYK2 introduction, etc. Non Receptor Tyrosine Protein Kinase TYK2 Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Non Receptor Tyrosine Protein Kinase TYK2 market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Non Receptor Tyrosine Protein Kinase TYK2 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Non Receptor Tyrosine Protein Kinase TYK2 key manufacturers include Array BioPharma Inc, Bristol-Myers Squibb Company, Nimbus Therapeutics LLC, Pfizer Inc, Portola Pharmaceuticals Inc, Sareum Holdings Plc, Takeda Pharmaceutical Company Ltd and Theravance Biopharma Inc, etc. Array BioPharma Inc, Bristol-Myers Squibb Company, Nimbus Therapeutics LLC are top 3 players and held % sales share in total in 2022.
Non Receptor Tyrosine Protein Kinase TYK2 can be divided into ARRY-624, BMS-986165, Cerdulatinib and NDI-031232, etc. ARRY-624 is the mainstream product in the market, accounting for % sales share globally in 2022.
Non Receptor Tyrosine Protein Kinase TYK2 is widely used in various fields, such as Follicular Lymphoma, Hypersensitivity, Lupus Nephritis and Marginal Zone B-cell Lymphoma, etc. Follicular Lymphoma provides greatest supports to the Non Receptor Tyrosine Protein Kinase TYK2 industry development. In 2022, global % sales of Non Receptor Tyrosine Protein Kinase TYK2 went into Follicular Lymphoma filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Non Receptor Tyrosine Protein Kinase TYK2 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Array BioPharma Inc
Bristol-Myers Squibb Company
Nimbus Therapeutics LLC
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Takeda Pharmaceutical Company Ltd
Theravance Biopharma Inc
Segment by Type
ARRY-624
BMS-986165
Cerdulatinib
NDI-031232
Others
Segment by Application
Follicular Lymphoma
Hypersensitivity
Lupus Nephritis
Marginal Zone B-cell Lymphoma
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Non Receptor Tyrosine Protein Kinase TYK2 market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Non Receptor Tyrosine Protein Kinase TYK2, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Non Receptor Tyrosine Protein Kinase TYK2 industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Non Receptor Tyrosine Protein Kinase TYK2 in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Non Receptor Tyrosine Protein Kinase TYK2 introduction, etc. Non Receptor Tyrosine Protein Kinase TYK2 Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Non Receptor Tyrosine Protein Kinase TYK2 market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.